Trending Now
Business
Do Creditors Know Eagle Pharma May Have Sunk The Company?
Eagle Pharma (EGRX) is an integrated pharmaceutical company that works with collaborators to help patients address unmet needs. The company is capable...
GE Shocks Investors Again
Tuesday General Electric (GE) announced it would take a fourth quarter after-tax charge of $6.2 billion related to its insurance business. The company just...
Lifestyle today
Entertainment
LeBron In Gangsta Mode After Binge Watching Ozark Season 2
Ozark is the latest Netflix drama series that is likely to go viral. The story centers around Mary Byrde (Jason Bateman) and Wendy Byrde...
Celgene: Revlimid’s Price Hikes Could Test Senate’s Resolve
Celgene (CELG) missed on Q3 revenue and gave weak forward guidance. Other than weak guidance the quarterly results looked fine. Top line growth was...
Jamie Foxx Disses ESPN’s Michael Smith Over A Katie Holmes Question
The NBA All-Star Game brings out a throng of celebrities. The NBA has even enjoined them in the festivities to the point where the...
Ohio AG Dave Yost Is Tweaking So Hard, Snowfall’s Skully Is Taking Pictures
The opioid crisis is front and center in the American consciousness. Opioid overdoses have claimed hundreds of thousands of lives. The crisis has drawn...
The Burning Bra – Victoria’s Secret Sale Could Be In Jeopardy
According to Women's Wear Daily, the sale of Victoria's Secret by L Brands (LB) could be in jeopardy:
Parent company L Brands’s deal to sell...
Endo Will Be Acquired Before Gilead
Endo International (ENDP) is still one of the market's most frustrating, confounding stocks. The stock hit a 52-week high of over $18 in the...
Johnson & Johnson’s COVID-19 Vaccine Could Punish Moderna, Novavax
Back in November it was uncertain whether big pharma could develop a vaccine to combat the coronavirus. Today at least four firms have garnered...
Generic Restasis Risk Metastasizes To Shire
Earlier this week Judge William Bryson ruled Allergan's (AGN) Restasis patents were invalid, and expressed serious concerns about Allergan's decision to transfer the patents...






















































































































